The pharmaceutical projects listed in this phase are those that receive periodic global announcements.
Kyowa Kirin, Inc, a global specialty pharmaceutical company headquartered in Japan, has announced plans to invest up to $530 million in building a new manufacturing facility in Sanford, North Carolina
Merck, a leading science and technology company, is investing 62 million in a new quality control facility for its Life Science division at its Darmstadt headquarters
AstraZeneca has announced plans to invest $15 billion in a new manufacturing facility in Singapore dedicated to antibodydrug conjugates
AbbVie has initiated the construction of its new central research facility, LUnA, at its main campus in Ludwigshafen, RhinelandPalatinate, Germany
GEA has announced a substantial investment of 80 million to enhance pharmaceutical production standards at its Elsdorf factory, aiming to modernize facilities and improve operational efficiency
Abzena, a leading CDMO for complex biologics and bioconjugates, announced a significant expansion of its Bristol, PA site for bioconjugate development and cGMP manufacturing
Sandoz, a global leader in generic and biosimilar medicines, opens new production facility in Kundl, Austria Facility aims to provide affordable lifesaving drugs solely manufactured in Europe,
AbbVie commenced the construction of a new expansion at its Singapore manufacturing facility, emphasizing its commitment
AGC Biologics is planning to build a new manufacturing facility at AGC Incs Yokohama Technical Center in Japan This expansion is part of AGC Biologics strategic growth strategy to enhance pharmaceutical development
FUJIFILM Cellular Dynamics, specializing in human induced pluripotent stem cells and iPSCderived cells, and FUJIFILM Diosynth Biotechnologies in California, a prominent CDMO in biologics and advanced therapies,
